Last Updated: September 28, 2026

Ge Healthcare Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for GE HEALTHCARE

GE HEALTHCARE has fifty approved drugs.

There is one US patent protecting GE HEALTHCARE drugs.

Summary for Ge Healthcare

US Patents:	1
Tradenames:	57
Ingredients:	39
NDAs:	50

Drugs and US Patents for Ge Healthcare

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	ISOPAQUE 440	calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium	INJECTABLE;INJECTION	016847-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Ge Healthcare	NEPHROFLOW	iodohippurate sodium i-123	INJECTABLE;INJECTION	018289-001	Dec 28, 1984		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Ge Healthcare	CLARISCAN	gadoterate meglumine	SOLUTION;INTRAVENOUS	210016-003	Nov 1, 2019	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Ge Healthcare	VISIPAQUE 320	iodixanol	INJECTABLE;INJECTION	020351-002	Mar 22, 1996	AP	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Ge Healthcare	OMNIPAQUE 240	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	020608-001	Oct 24, 1995		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Ge Healthcare

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	MPI DMSA KIDNEY REAGENT	technetium tc-99m succimer kit	INJECTABLE;INJECTION	017944-001	May 18, 1982	4,233,285	⤷ Start Trial
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-002	Oct 25, 2013	7,351,401	⤷ Start Trial
Ge Healthcare	OMNIPAQUE 350	iohexol	SOLUTION;INJECTION, ORAL	018956-004	Dec 26, 1985	4,250,113	⤷ Start Trial
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-001	Oct 25, 2013	8,691,185	⤷ Start Trial
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020808-001	Aug 29, 1997	RE36418	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for Ge Healthcare Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Russian Federation	2475267	⤷ Start Trial
Spain	2464715	⤷ Start Trial
Japan	5367708	⤷ Start Trial
Denmark	2182988	⤷ Start Trial
South Africa	201000718	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Ge Healthcare Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3752510	122025000060	Germany	⤷ Start Trial	PRODUCT NAME: VANZACAFTOR, ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON, BEVORZUGT EIN CALCIUMSALZ DAVON; REGISTRATION NO/DATE: EU/1/25/1943 20250630
1853250	2014C/037	Belgium	⤷ Start Trial	PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230
2957286	CR 2018 00043	Denmark	⤷ Start Trial	PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REG. NO/DATE: EU/1/17/1179/001-009 20170721
1853250	CA 2014 00034	Denmark	⤷ Start Trial	PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: EU/1/07/428 C(2013)9835 20131230
2957286	6/2019	Austria	⤷ Start Trial	PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.